Infomerics upgrades Morepen Laboratories to IVR A

What happened

In a filing with the BSE on 14 November 2026 at 11:38 AM, Morepen Laboratories (MOREPENLAB) said that Infomerics has upgraded its credit rating to IVR A.

From the filing: "the SEBI Listing Regulations , w e wish to inform that Infomerics Valuation and Rating Limited ( " INFOMERICS " ) , a SEBI registered Credit Rating Agency , vide its letter dated 13 th November 2026, has upgraded the rating of bank facilities of the company to IVR A/ Stable ."

Company snapshot

Morepen Laboratories is a small-cap company, with a market value of about ₹5,200 crore.

The stock last traded at ₹94.9, against a 52-week range of ₹33.05–₹150.7 (37.0% below the high).

Before this filing the shares had moved −22.4% over the month and +17.3% over three months. Average daily turnover over the last 20 sessions was about ₹55.36 crore.

Promoters held 35.65% at the end of Q2 FY27. Foreign institutions owned 3.43% and domestic institutions 1.71%.

What history shows

BCEIE has no earlier credit rating filing from this company on record since May 2026.

Market-wide, 1,468 credit rating filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 48% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• Whether other agencies take a similar view on the company's credit.

In the news

Recent coverage elsewhere (links open the original publisher):

• Morepen Laboratories VP Nishant Doshi Resigns — Medical Dialogues, 2 Nov 2026
• Morepen Laboratories Enters US Prescription Generics Market with Desloratadine Launch — Machine Maker, 13 Nov 2026
• Morepen Laboratories Limited (MOREPENLAB.NS) Seasonal returns chart — Yahoo Finance Australia, 1 Nov 2026
• Morepen Laboratories VP Corporate Finance Nishant Doshi resigns — scanx.trade, 31 Oct 2026
• Morepen Laboratories Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent — MarketsMojo, 13 Nov 2026

Source

• Exchange filing (PDF)